Cisatracurium perchè

Perché il cisatracurium:Nimbex
Claudio Melloni
l.p.
Già Direttore UO Anestesia e Rianimazione Ospedale di
Faenza

Servizio di Anestesia e Rianimazione Ospedale di Faenza(RA)

Problemi di sicurezza dei miorilassanti

Fast onset

Fast offset

No blocco residuo
No blocco residuo

Profilo
di
sicurezza

Valutazione
rischio/beneficio

No liberazione di
istamina;
no effetti emodinamici

Evita antagonismo
Evita antagonismo

No metaboliti attivi
No metaboliti attivi
Indipendenza da organi

Mancanza effetti collaterali

Facile
Facile conservabilità/utilizzo
sicurezza


conservabilità e

Dinamica


Tempo dalla iniezione

T1 75%

T1 5%

T1 25%


RI,ossia recovery index...:min
100
90
80
70
60
% 50
40
30
20
10
0

RI 5-95

RI 25-75

RI 5-25

T1/TC
5

T1/tc
25

T1/tc
75


T1/TC
95

2*ED95 dei principali miorilassanti
farmaco

Dose(mg/kg)

Succinilcolina

1,0

Rocuronium

0,6

Vecuronium

0,1

Atracurium

0,5

Mivacurium

0,2

Cisatracurium

0,1


onset del cisatracurium
7.12
6.00
0.05 mg/kg
0.1 mg/kg
0.1 mg/kg bambini
0.2 mg/kg
0.4 mg/kg

4.48
3.36
2.24
1.12
0.00

onset


Onset(sec) dei principali
miorilassantia 2*ED95.
succinilcolina
rocuronium
vecuronium
atracurium
mivacurium
cisatracurium

180,0
160,0
140,0
120,0
100,0
80,0
60,0
40,0
20,0
0,0

onset


Durate e riprese dei principali miorilassanti
a 2ED95
50
45
40
35
30
min 25
20
15
10
5
0

succi
rocu
vecu
atrac
miva
cis

dur T1 25%


R 25-75%

Farmacodinamica del
cisatracurium(Sorooshian,Anesthesiology 1996)
120
min
100

2 mg:giov
2 mg anzi
4 mg giov
4 mg anzia
6 mg giov
6 mg anzia
8 mg giov
8 mg anzia
10 mg giov
10 mg anzia

80
60
40
20
0

onset

T1 25%

T1 75%


RI 25-75%

Farmacodinamica del
cisatracurium
dati da Belmont(A.,1995,82,1139)
min
140

0.1 mg/kg

120

0.2 mg/kg

100

0.4 mg/kg

80

inf cont

60
40
20
0

t125%

T195%

T4/T1>70%


RI25-75%

RI5-95%

Dati da Bluestein

Bluestein LS,Stinson L W, Lennon R L ,Quessy S N.,Wilson
RM. Evaluation of cisatracurium, a new neuromuscular blocking agent, for tracheal intubation. CAN J
ANAESTH 1996 / 43: 9 / pp925-31

70

N2O,propofol,fentanyl

60
0.1 mg/kg

50
min

0.15 mg/kg

40

0.2 mg/kg

30
20
10
0

t125%

RI25-75%


onset

Tof 0.70 dopo
reversal

Clinical profile
cisatracurium 0.15 mg/kg

cisatracurium

NIMBEX

Recovery Index

0.1 mg/Kg

0.2 mg/Kg

0.4 mg/Kg

Belmont MR.,Anesthesiology 1995

infusione

Bluestein LS,Stinson L W, Lennon R L ,Quessy S N.,Wilson RM.
Evaluation of cisatracurium, a new neuromuscular blocking agent, for
tracheal intubation. CAN J ANAESTH 1996 / 43: 9 / pp925-31

bolo 0.1-0.4 mg/kg
INDICE 25-75%: 12,6-14,4 min.
infusione continua:1.4 mcg/kg/min.
INDICE 25-75%: 15 min.


Farmacodinamica del cisatracurium
nell’anziano(Ornstein et
al,Anesthesiology,1996,84,520)

90
80
70
60
50

anziani
giovani

40
30
20
10
0

*
onset

t1 5% T1 25% T1 75% T1 95% TOF 70


Imbeault K, Withington DE, Varin F. Pharmacokinetics and
pharmacodynamics of a 0.1 mg/kg dose of cisatracurium
besylate in children duringN2O/O2/propofol
anesthesia.Anesth Analg. 2006 Mar;102(3):738-43
50
45
40
35
30
min 25
20
15
10
5
0

onset

T1 25%


T1 75%

RI 25-75%

tempi di ripresa 25-75% di alcuni
miorilassanti
18
16
14
12
10
8
6
4
2
0

cisatr
vecu
rocu
atrac
miva inf

RI 25-75%


Tempi di ripresa al T1 25% in pazienti anziani dopo 2ED95 di
cisatracurium,vecuronium,rocuronium.da

Arain SR,Kern S, Ficke DJ,
Ebert TJ. Variability of duration of action of neuromuscular-blocking drugs in elderly patients.
Acta Anaesthesiol Scand. 2005 Mar;49(3):312-5.

160

Preop midazolam 1 mg
induction 5 mg kg(-1) TPS
+2 microg kg(-1) fent.
0.6 mg kg(-1) rocuronium,
0.1 mg kg(-1) vecuronium
or 0.1 mg kg(-1) cisatracurium.
maintenance sevoflurane in O2/N2O

140
120
min

100
80
60

max

40

min

20

variabilità mediana

0
cis

rocu


vecu

Cinetica


Tran TV,Fiset P, Varin F.Pharmacokinetics and
pharmacodynamics of cisatracurium after a short infusion
under propofol anesthesia.Anesth.Analg 1998;57:1158
118

120
100
80
60
40
20
0

24
3.7

Cl ml/kg/min
V1
Vss ml/kg
T 1/2 min

Farmacocinetica del cisatracurium
nell’anziano(Ornstein et al,Anesthesiology,1996,84,520)
140

126 *

120

108

100
80
57.857.2

60

*

40
20
0

25.521.5
5 4.6
Clp

V1

Vss


T 1/2 beta

anziani
giovani

Farmacocinetica del cisatracurium
nell’anziano(Sorooshian et al,Anesthesiology,1996)
350

319319

300
250
200
anziani
giovani

150
100
47.6 47

50
0

13.3 9.7
Clp ml/min

V1 lt

Vss lt


36.3
28.4
T 1/2 beta
min

dati farmacocinetici del cisatracurium nel bambino e
nell'adulto:dati da Tan e Sorooshian (giovani) per gli adulti e
Imbeault per i bambini
160,0

Clml/kg/min

140,0

V1 ml/kg

120,0

Vssml/kg

*

100,0

EC 50 micr/ml

80,0

t 1/2

60,0
40,0
20,0
0,0

*
bambino

*
adulto Tan


adulto
Sorooshian

Antagonizzazione


Kirkegaard H,Heier T,Caldwell JE Efficacy of tactile guided
reversal from cisatracurium induced neuromuscular
block.Anesthesiology 2002;96:45-50

Anest with fent/prop/N2O
cisatrac 0.15 mg/kg
neostigmine 0.07 mg/kg administered at
reappearance of I,II,III,IV of TOF;tactile
vs Meccanomyography contralateral.


Time from neostigmine administration
to TOFR 0.70
25.00
20.00
low
max
min
mediana

15.00
10.00
5.00
0.00
I twitch

II twitch

III twitch


IV twitch

to TOFR 0.80
35
30
25

low
max
min
mediana

20
15
10
5
0
I twitch

II twitch

III twitch


IV twitch

to TOFR 0.90
80
70
60
low
max
min
mediana

50
40
30
20
10
0
I twitch

II twitch

III twitch


IV twitch

Kirkegaard H,Heier T,Caldwell JE Efficacy of tactile guided
reversal from cisatracurium induced neuromuscular
block.Anesthesiology 2002;96:45-50

This study shows that achieving a TOFR
of 0.90 in <10 min following neostigmine
reversal is not a realistic goal;therefore
counting the number of tactile responses to tof stimulation
cannot be used as a guide for neostigmine admninistration if
the end point of reversal is a TOFR of 0.90 or higher within
10 min;but

is a good predictor of TOFR

0.70.

MMG magnitude of the first TOF twitch(T1) measured at the
reappearance of each of the 4 tactile TOF responses.
80
70

T1 %

60
low
max
min
mediana

50
40
30
20
10
0
I twitch

II twitch

III twitch


IV twitch

Correlazione soggettiva-oggettiva(palpazionemeccanomiografia)

1 Twitch= T110%
3 twitches=T1 25%


Conclusioni sull’antagonismo
Poiché è noto fin dagli anni ’70 che un TOF di 0.70 è
sufficiente per una ventilazione spontanea,tanto ci
basta !
Nessuno poi deve cessare immediatamente la
sorveglianza del paziente….
Non si fa così anche con la TIVA/TCI???


non cumulatività del cisatracurium

Belmont

MR,Lien CA,Quessy S,Abou-Donia MM,Abalos A,Eppich L,Savarese JJ.The clinical neuromuscular
pharmacology of 51W89 in patients receiving nitrous oxide/opioid /barbiturate anesthesia.Anesthesiology
1995;82:1139-45.

Intervallo in min fra le dosi refratte o velocità medie di
infusione per un blocco del 95%
25
min
20
15

dosi rip
inf cont

10
5
0

microgr/kg/min
I

II

III

IV

V

VI


VII VIII IX

X

Belmont MR,Lien CA,Quessy S,Abou-Donia MM,Abalos A,Eppich
L,Savarese JJ.The clinical neuromuscular pharmacology of 51W89 in
patients receiving nitrous oxide/opioid /barbiturate
anesthesia.Anesthesiology 1995;82:1139-45.


Diluizione del cisatracurium
1 microgr/kg/min significa 70 microgr/min per un
peso di 70 kg,4.2 mg /h ; se abbiamo diluito 10
mg in 50 ml abbiamo 200 Microgr/ml e la velocità
è 21 ml/h;
1.5 microgr/kg/min per un peso di 70 kg significa
105 microgr/min cioè circa 6 mg/h ,che alla
diluizione di cui sopra valgono 30 ml/h

Cisatracurium e insufficienze
d’organo


De Wolf AM.,Freeman JA, Scott VL,Tullock W,Smith DA,Kisor DF,
Kerls S,Cook,DR. Pharmacokinetics and pharmacodynamics of
cisatracurium in patients with end-stage liver disease undergoing liver
transplantation. Br. J. Anaesth. 1996; 76:624-628
200
180
160
140
120
100
80
60
40
20
0

liver transpl
normal

Vd ml/kg

Clp ml/kg/min

T 1/2 min

T1 25


RI 25-75

Peak
laudanosine
conc

ng/ml

farmacodinamica del rocuronium nei cirrotici(da Boyd et
al,Bja,1994,73,262p)

rocu 0.6 mg/kg,isoflurane 0.6%
min
140
120
100
80
60
40
20
0

*
sani
cirrotici

T110% T125% T175%


RI2575%

Tof70

Repeated doses of rocuronium in cirrhotic and control
patients receiving isoflurane(Servin et
al.,Anesthesiology,1996,84,)1092
min

50
45
40
35
30
25
20
15
10
5
0

cirrotici
normali

T1 25% T1 25% T1 25% T1 90%
a 75
150
225
microgr micrg micrg


TOF
70%

RI 2575%

Mivacurium e insufficienza epatica
50

dati da Devlin et al.,BJA,1993

40
30
20

norm
cirrotici

10
0

t15%

t110%

t125%

t150%


t175%

tof70%

RI25-75%

Rocuronium nella insuff renale ed
epatica
dati da Magorian,Khalil e Szenohradsky
80
min

70
60
50
40
30
20
10
0

normali
insuff ren
insuff epati

t1/tc25%

t1/tc50%

t1/tc75%


t1/tc90%

RI25-75%

R125-75%

Variazioni % dei tempi di ripresa dei miorilassanti nella
insuff.epatica dati medi da diverse ref:bibliografiche
60

aumento %

50

rocu ins epat
rocu cirrosi
vecu
atrac
cisatrac
mivac

40
30
20
10
0

T 1 25

T1 90


RI 25-75

Cisatracurium in ICU


Ripresa neuromuscolare dopo infusione
prolungata in ICU:da Prielipp et al.
cisatracurium

vecuronium

Recovery time after 68 +/- 13 min.
discontinuation:min
to tof 0.70

387 +/- 163 min,

Prolonged
paralysis:patients

13

2


Ripresa neuromuscolare in ICU dopo infusione di
miorilassanti in neonati sottoposti a chirurgia cardiaca;da
Reich e coll
cisatracurium

vecuronium

Time to no fade in 30
TOFR:min

180

Prolonged
paralysis:patients

3

0


Infusion of muscle relaxants in critically ill children
requiring mechanical ventilation in ICU,da
Burmester
cisatracurium

Time to
recovery,min

vecuronium

(52 ,range 35-73)
than with

123 ,range , 80480).

Prolonged recovery 0
of neuromuscular
function (>24 h)

1

Effetti emodinamici


Wastila WB,Maehr RB The pharmacological profile of
51w89,the R cis-R’ cis isomer of atracurium in
cats.Anesthesiology 1993;79,abstract A 946.
30
25
20
cisatrac
atrac
vecu

15
10
5
0

ID50 vagal/nmED95

Belmont et al.Comparative pharmacology of atracurium and
one of its isomers 51w89 in rhesus monkeys.Anesthesiology
1993;79:Abstract A 947.
Variazioni % rispetto al basale fino a 14
ED95
2 animali con flushing

20
18
16
14
12
10
8
6
4
2
0

% HR


% MAP

cisatrac
atrac

Lien CA,Belmont MR,Abalos A,Eppich L,Quesny S,Abou-Donia
MM,Savarese J. The cardiovascular effects and histamine releasing
properties of 51W 89 in patients receiving nitrous oxide-opioid/
barbiturate anesthesia.Anesthesiology 1995;82:1131-38.

ASA 1 & 2
anest:midaz/fent/tps
iot senza miorilass
campionamento sangue venoso + monitoraggio
intraarterioso continuo per PA.
SIu8 Grass 0.15 Hz,ST,meccanomiografia
boli in 5 sec di cis: 2 ED5,4 Ed95,8 Ed95

Lien CA,Belmont MR,Abalos A,Eppich L,Quesny S,Abou-Donia
MM,Savarese J. The cardiovascular effects and histamine releasing
properties of 51W 89 in patients receiving nitrous oxide-opioid/
barbiturate anesthesia.Anesthesiology 1995;82:1131-38.


Reich DL, Mulier J, Viby-Mogensen J, Konstadt SN,van Aken
HK,Jensen FS,De Perio M, Buckley S. Comparison of the cardiovascular
effects of cisatracurium and vecuronium in patients with coronary artery
disease .Can J Anaesth 1998 / 45 / 794-797

cisatracurium, 0.20 mg×kg-1 (4 x ED95)
cisatracurium, 0.30 mg×k-1 (6 x ED95)
vecuronium, 0.30 mg×kg-1 (6 x ED95)
cisatracurium, 0.40 mg×kg-1(8 x ED95)
vecuronium. 0.30 mg×kg-1 (6 x ED95)
. The haemodynamic measurements were repeated at 2,
5, and 10 min after cisatracurium or vecuronium.
The haemodynamic changes from pre- to postinjection in the cisatracurium patients were minimal
and similar to patients receiving vecuronium.

Haemodynamic stability after initial dose(Puhringer et al)
No HR/BP changes
HR or BP changes requiring drug treatment

n = 137

n = 140
4.1%

0%

cisatracurium
0.15 mg/kg

vecuronium
0.1 mg/kg

Liberazione di istamina


Lien et al. The cardiovascular effects and histamine releasing properties
of 51W 89 in patients receiving nitrous oxide-opioid/barbiturate
anesthesia. Anesthesiology 1995;82:1131-38


Schramm WM,Papousek A,Michalek-Sauberer A, Czech
T,Illievich U. The Cerebral and Cardiovascular Effects of
Cisatracurium and Atracurium in Neurosurgical Patients .
Anesth Analg 1998; 86:123–7

Paz ICU sedati,intub e
ventilati
Cis 0.15 mg/kg vs atrac 0.75
mg/kg
Effetti NCh scomparsi dopo
rimoss dallo studio dei 5 paz
con evidente flush cutaneo


Schramm WM,Papousek A,Michalek-Sauberer A, Czech
T,Illievich U. The Cerebral and Cardiovascular Effects of
Cisatracurium and Atracurium in Neurosurgical Patients .
Anesth Analg 1998; 86:123–7

0

Cisatra

-5

Atrac

-10

ICP

CPP

CBFV
Transcranial
Doppler

MAP


HR

Atrac

-20

Cisatrac

²

-15

Quoziente di sicurezza:
ED95 istaminoliberatrice/ED95 blocco nm.
8
7

??

6
5
4
3
2
1
0

safety factor


Dtc
metoc
atrac
mivac
cisatrac

Reazioni allergiche attribuite ai miorilassanti
in %;da
Laxenaire MCEpidemiology of anesthetic anaphylactoid reactions. Fourth multicenter survey (July 1994-

December 1996)]
Ann Fr Anesth Reanim. 1999 Aug;18(7):796-809.

30,00
25,00
20,00
% 15,00

69.2% delle 477
reazioni allergiche
durante anestesia
in Francia

10,00
5,00
0,00

reaz allergiche


cisatracurium
atracurium
mivacurium
pancuronium
vecuronium
rocuronium
succinilcolina

Strategie per attenuazione della
liberazione di istamina
Iniezione lenta (30 sec);
Pretrattamento con antiistaminici…..


Miorilassanti e reazioni
anafilattiche


Laxenaire MC, Mertes PM, Benabes B, et al. Anaphylaxis
during anaesthesia: results of a two-year survey in France. Br
J Anaesth 2001; 87:549-58.


Laxenaire MC, Mertes PM, Benabes B, et al. Anaphylaxis
during anaesthesia: results of a two-year survey in France. Br
J Anaesth 2001; 87:549-58.

8%

4% 3% 2% 2%
miorilass

%

latex
antibiotici
ipnotici
colloidi

69%

oppioidi
altri

Vedi per la ref il testo per glaxo
2008
Links
Comment in:
Anesth Analg. 2004 May;98(5):1499-500; author reply 1500.
Anesth Analg. 2004 May;98(5):1499; author reply 1500.
Anesth Analg. 2004 May;98(5):1499; author reply 1500.
Anaphylaxis during the perioperative period.
Hepner DL, Castells MC.
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital, Harvard
Medical School, Boston, Massachusetts 02115, USA. dhepner@partners.org
Anesthesiologists use a myriad of drugs during the provision of an anesthetic. Many of these drugs have
side effects that are dose related, and some lead to severe immune-mediated adverse reactions.
Anaphylaxis is the most severe immune-mediated reaction; it generally occurs on reexposure to a specific
antigen and requires the release of proinflammatory mediators. Anaphylactoid reactions occur through a
direct non-immunoglobulin E-mediated release of mediators from mast cells or from complement activation.
Muscle relaxants and latex account for most cases of anaphylaxis during the perioperative period.
Symptoms may include all organ systems and present with bronchospasm and cardiovascular collapse in
the most severe cases. Management of anaphylaxis includes discontinuation of the presumptive drug (or
latex) and anesthetic, aggressive pulmonary and cardiovascular support, and epinephrine. Although a
serum tryptase confirms the diagnosis of an anaphylactic reaction, the offending drug can be identified by
skin-prick, intradermal testing, or serologic testing. Prevention of recurrences is critical to avoid mortality and
morbidit


Un poco di biblio sulla anafilassi ai
miorilassanti…..
Laxenaire MC. Epidemiologie des reactions anaphylactoides
peranesthesiques: quatrieme enquete multicentrique (juillet 1994decembre 1996) Ann Fr Anesth Reanim 1999; 18:796-809.
Laxenaire MC, Gastin I, Moneret-Vautrin DA, et al. Cross reactivity of
rocuronium with other neuromuscular blocking agents. Eur J
Anaesthesiol 1995; 11:S55-64.
Neal SM, Manthri PR, Gadiyar V, Wildsmith JA. Histaminoid reactions
associated with rocuronium. Br J Anaesth 2000; 84:108-11.


Rocuronium?
Guttormsen AB. Allergic reactions during
anaesthesia: increased attention to the problem in
Denmark and Norway. Acta Anaesthesiol Scand
2001; 45:1189-90.
» 55 reazioni al rocuronium con 3 decessi:
» ”Dear Doctor letter” con raccomandazioni per
evitarne l’uso eccetto le intubazioni d’urgenza!!

Rose, M.; Fisher, M. Rocuronium: high risk for anaphylaxis?
Br. J. Anaesth. 2001; 86:678-682
ABSTRACT: Patients suspected of anaphylaxis during anaesthesia
have been referred to the senior author's clinic since 1974 for
investigation. Since release of rocuronium on to the worldwide market,
concern has been expressed about its propensity to cause
anaphylaxis. We identified 24 patients who met clinical and laboratory
(intradermal, mast cell tryptase and morphine radioimmunoassay)
criteria for anaphylaxis to rocuronium. The incidence of rocuronium
allergy in New South Wales, Australia has risen in parallel with sales,
while there has been an associated fall in reactions to other
neuromuscular blocking drugs. Data from intradermal testing
suggested that rocuronium is intermediate in its propensity to cause
allergy in known relaxant reactors compared with low-risk agents (e.g.
pancuronium, vecuronium) and higher-risk agents (e.g. alcuronium,
succinylcholine).

Rose, M.; Fisher, M. Rocuronium: high risk for
anaphylaxis? Br. J. Anaesth. 2001; 86:678-682


Current controversy revolves around the potential for an increased incidence of anaphylaxis
to rocuronium when compared with other muscle relaxants . The increased number of
allergic reactions to rocuronium in Norway—55 reactions and 3 deaths over 4 yr—led to a
“dear doctor letter” from the Norwegian Medicines Agency that recommended rocuronium's
withdrawal from routine practice and its use reserved for urgent intubations . There is a
discrepancy between the reported incidence of anaphylaxis due to rocuronium in Norway (1
in 3,500 anesthetics) and the incidence noted in the United States (1 in 445,000
anesthetics; 80% of worldwide use) . This discrepancy has been attributed to multiple
factors, including false-positive testing, increased use of the drug, statistical challenge, and,
possibly, population genotype differences . Rocuronium may cause a wheal and flare
response independent of mast cell degranulation. Levy et al. demonstrated that intradermal
skin testing with rocuronium at concentrations larger than 10-4 M (609.70 g/L = 1 M)
produced a positive wheal or flare response in 29 of 30 volunteers in the absence of mast
cell degranulation. These authors suggest that skin testing with concentrations larger than
10-4 M may account for some of the reported cases of rocuronium allergy reported in
Europe . A report from Australia, using a 1:1000 dilution for intradermal skin testing,
demonstrated that rocuronium is intermediate in its potential to cause anaphylaxis . This
study also demonstrated that the increased incidence of anaphylaxis due to rocuronium in
Australia is a result of its increased use . Statistical challenges, such as small sample size
and biased reporting of newer drugs, may account for the increased incidence of
rocuronium anaphylaxis

Quote di mercato in Francia tra
gennaio 1999 e dicembre 2000
(306)
6%

4%

7%

9%

11%

10%
53%

succinilcolina
atracurio

rocuronio
mivacurio


vecuronio
cisatracurio

Curari responsabili di 336 reazioni
anafilattiche tra il 1997 ed il 1998
21,1%
29,2%
17,6%

0,3%
rocuronio

mivacurio

2,7%

cisatracurio

vecuronio

Mertes et al. An. Reanim, 2003, 36: 410-A


atracurio

Casi di shock anafilattico attribuiti ai curari in
Francia tra gennaio 1999 e dicembre 2000 (306)
2,6%
19%

0,6%
22,6%

succinilcolina
rocuronio
vecuronio

3,3%

pancuronio
atracurio

8,5%

mivacurio
cisatracurio
43,1%

QM rocuronio + succinilcolina = 16%
65% dei casi di anafilassi

Risk of allergic reactions caused by
NMB’s (ratio)

Mertes 2003
Laxenaire 2001
Laxenaire 2000
Laxenaire 1999

succi

rocu

panc

vecu

miva

atrac


cisatr

Anesthesia with or without curare? Christophe
Baillard,Philippe Larmignat, Jean Luc Fournier
Christophe Denantes , Michel Cupa , Charles Marc Samama
To the Editor:
Anaphylactic reactions are a common complication of anesthesia, most often related to the use of muscle relaxants. The intensity varies from
mild clinical manifestations to severe anaphylactic shock and death. With increased public awareness and the improvement in the detection and
diagnosis of such adverse events, an increased frequency has been reported in most developed countries.
In France, a recent survey estimated the incidence of anaphylactic reactions to be as high as one amongst 6,500 anesthetic procedures when
a muscle relaxant is used. Approximately four individuals per 100 population (2.5 million) receive muscle relaxants during anesthesia every year.
These data allow us to postulate that among the French population alone (60 million people), 350 patients every year will develop a muscle
relaxant mediated anaphylactic reaction. Similarly, thousands of patients all over the world will experience similar adverse events. Risk reduction
requires that the use of muscle relaxants be limited inasmuch as possible since anaphylaxis may occur in patients with or without a previous
history of allergy.
To date, there are two main indications for muscle relaxants during anesthesia for elective surgery. The first involves the anesthetic procedure
itself, i.e., tracheal intubation, while the second relates to the surgical procedure. Muscular relaxation facilitates airway management, access to
the surgical site, closure of the abdominal wall and avoids inopportune movements. However, muscle relaxants are no longer mandatory.
There is now evidence that the development of new hypnotic drugs has changed airway management and allows tracheal intubation without
the need for muscle relaxants in a selected population. From a surgical point of view, abdominal and thoracic procedures usually require
muscular relaxation but, on the other hand, numerous peripheral surgical procedures such as lower abdominal and limb operations do not
require the use of curare.
While recent data show that it is possible to intubate the trachea without resorting to muscle relaxants, the topic remains controversial.
Intubating habits vary both locally and internationally. It has been suggested that muscle relaxants decrease pharyngeal and laryngeal trauma
secondary to intubation. As a result, several anesthesiologists are reluctant to curtail muscle relaxation for intubation. In 1996, in France, only
16% of anesthetics requiring tracheal intubation were conducted without the use of muscle relaxants.
This puts us in a delicate situation. As anesthesiologists, we use a class of drugs, muscle relaxants, known to mediate anaphylaxis with
potentially life-threatening consequences whereas, on the other hand, there is no more doubt that we are able to avoid these drugs in many
situations.
Should we still widely use muscle relaxants or should we restrict their prescription? Patient safety during anesthesia requires us to take into
account all risks, even those that may have been underestimated in the past.


Bhananker SM,O'Donnell JT., Salemi JR,Bishop MJ.
The risk of anaphylactic reactions to rocuronium in the USA is
comparable to that of vecuronium:an analysis of FDA reporting on
adverse events.Anesthesia Analgesia 2005,101,819-822
):
ABSTRACT: Published reports from France and Norway suggest a frequent incidence of anaphylaxis to
rocuronium and have raised concerns about its safety. We hypothesized that the Food and Drug
Administration Adverse Event Reporting System could be used to confirm whether there has been an
unusual incidence of anaphylactic events for rocuronium in the United States (U.S.) and whether the
reporting patterns differ within and outside of the U.S.. We queried the Food and Drug Administration
Adverse Event Reporting System for 1999 through the first quarter of 2002 for all adverse events for the
drugs rocuronium and vecuronium and then searched on the terms considered to represent possible
anaphylaxis using proprietary software. We compared the frequency of these terms in data both for
rocuronium and vecuronium. We then assessed the occurrence of reports of anaphylaxis-related terms in
reports from the U.S. compared with reports originating outside of the U.S.. For rocuronium, the database
contained 311 reports, 166 domestic and 145 from foreign sources. Fifty percent of the foreign reports
contained an anaphylaxis term versus 20% of the domestic reports (P < 0.001). For vecuronium, the
comparable figures were 17% and 19% (not significant) and the total number of reports was 243. The
incidence of the reports containing anaphylaxis terms did not differ between vecuronium and rocuronium
in the U.S. but were significantly different for foreign reports (P < 0.001). These data confirm that U.S.
anesthesia providers have not observed a significant difference in anaphylactic reactions between the
two commonly used intermediate-acting muscle relaxants and suggest that frequency of reports of
anaphylaxis may be significantly influenced by the area from which the reports originate.


Bhananker
*Department of Anesthesiology, University of Washington School of Medicine, Seattle, WA; †Department of
Pharmacology, Rush Medical College, Chicago, IL; ‡Pharmaconsultant, Inc.,

Palatine, IL; and §Department of Veterans Affairs and the Departments
of Anesthesiology and Medicine (adjunct, Pulmonary and Critical Care),
University of Washington School of Medicine, Seattle, WA
Supported, in part, by the Office of Research and Development,
Department of Veterans Affairs, Seattle, WA.
Disclosure: Michael Bishop and James O'Donnell receive unrestricted
grant funding from Organon, Inc.
Presented, in part, at the annual meeting of the American College of
Clinical Pharmacology, Phoenix, Arizona, October 3–5, 2004.
Accepted for publication March 29, 2005.
Address correspondence and reprint requests to Sanjay M.
Bhananker, MD, FRCA, Department of Anesthesiology, Harborview
Medical Center, 325 9th Avenue, Seattle, WA 98104. Address electronic
mail to: sbhanank@u.washington.edu.


Struttura chimica del besilato di
cisatracurium(Nimbex)


Livelli plasmatici di laudanosina(

Eastwood,NB,Boyd

AH,Parker cir,Hunter,JM.Pharmacokinetics of 1r-cis1’rcis atracurium besylate(51W89)and plasma laudanosine concentrations
in health and chronic renal failure ,BJA 1995,75.431-5.
Fahey MR,Rupp SM,Canfell C,Mier RD,Sharma M,Castagnoli K,Hennis PJ.Effect of renal failure on laudanosine excretion in
man.BJA 1995;57:1049-51)

0.8
0.7
0.6
0.5

atrac

0.4

cis

0.3
0.2
0.1
0

sani


insuff ren

Chapple DJ, Miller AA, Ward JB, Wheatley PL: Cardiovascular and
neurological effects of laudanosine, BrJ Anaesth 1987; 59:218-25

Topi:dosi di laudanosina > 15 mg/kg →convulsioni
ratti:dosi > 14 mg/kg → convulsioni in tutti:nel 66% a
10 mg/kg,prevenute da prettrattamento con diaz
(34 mg/kg)(ED 50 2 mg/kg)
cani coscienti:boli di 2 e 4 mg/kg→
» agitaz(liv plasm 0.88+-0.16 µg /kg;1
salivaz,1 si
lecca di labbra;Hr aum di 41 bpm
» liv.plasm di 1-1.4 µg /ml:,no effetti comportamentali,ma
Hr aum.


Inf cont di laudanosina in cani
anestetizzati(haloth):a 10-17µg/ml di
conc plasma ,attività epilettogena in tutti
all’EEG:
HR ↑ poi↓ e BP↓
in tutti i cani l’attività epilettogena EEG
cessa dopo diaz i.v

Convulsioni cloniche
Spikes,polispikes,bursts parossisticiè+
mioclonie
Ch onde appuntite(spiking) e rapide

Aum.ampiezza e frequenza EEG


Hofmann degradation – a way to convert
quaternary amines to tertiary amines

pH and temperature dependent

A.W. Hofmann (1818-1892)

NIMBEX
NIMBEX vs TRACRIUM :
QUALE VANTAGGIO ?


1.

NIMBEX non libera istamina fino a 8 volte la ED95
 minimizzo il rischio di eventi avversi, anche rari;


uso in pazienti allergici

 Stabilità emodinamica

1.

l’eliminazione di Hofmann è reponsabile dell’80% della clearance di
Nimbex, verso il 40% di Tracrium
 recupero prevedibile in tutte le categorie di pazienti



1.

dopo infusioni prolungate
maggiore sicurezza durante estubazione in cui si perde il controllo
delle vie aeree

la quantità di laudanosina che si forma usando NIMBEX è 1/3
 minimo rischio di eventi avversi neurologici in pazienti sottoposti a
neurochirurgia

liberazione di istamina
DoenicKe, 1997


Effetti sulla pressione intraoculare
(IOP) di
2 x ED95 NIMBEX vs TRACRIUM
Atracurium

Cisatracurium

16
15
IOP (mmHg)

14
13
12
11
10
9
8
7
6
5
4
0

1

5

10

15

Time (min)

S.M. Sator-katzenschlager, M.J. Oehmke
European Journal of Anaesthesiology 2002; 19: 823-828

20

45

CIsatracurium nell’anziano
Vantaggi a confronto del vecuronium


Spontaneous Complete Recovery Time

25% T - TOF ratio 0.8 (min)
>
1

18 - 64 years

> 65 years

90
80
p < 0.001

70
60
50
40
30
20
10
0
cisatracurium


vecuronium

Variance in SCRT
Time Interval final 25%T1 to Tof Ratio >=0.8
140
120
100

minutes

80
60

Age Category

40

<65

20
0

>=65

N=

65

65

Nimbex
Treatment


63

56

Vecuronium

Clinical Duration of Block
18 - 64 years

> 65 years

Time to 25% T
1 (min)

70
60

p < 0.001

50
40
30
20
10
0

cisatracurium
0.15 mg/kg


vecuronium
0.1 mg/kg

Potenziamento :da parte dei vapori
anestetici,terapia anticonvulsivante


Richard A, Girard F, Girard DC, Boudreault D, Chouinard P,
Moumdjian R, Bouthilier A, Ruel M, Couture J, Varin F. Cisatracuriuminduced neuromuscular blockade is affected by chronic phenytoin or
carbamazepine treatment in neurosurgical patients.
Anesth Analg. 2005 Feb;100(2):538-44.

» La terapia anticonvulsivante cronica con
carbamazepina e fenitoina aumenta del 44% la
necessità di cis per mantenere costante un blocco
del 95%
» Aumenta la CL 7.12 vs 5.72 lt/kg
» Aumenta la Cp(ss)95 :191 +/- 45 versus 159 +/- 36
ng/mL, P = 0.04)
» Insomma, i paz in terapia anticonvulsivante cronica
necessitano di dosi maggiori a parità di profondità
di blocco,ossia hanno una ripresa più rapida,ossia
risultano più resistenti al cisatracurium

Wulf,H,Kahl,M,Ledowski,T.Augmentation of the
neuromuscular blocking effects of cisatracurium during
desflurane,sevoflurane,isoflurane or total i.v.anesthesia.British
Journal of Anesthesia 1998,80:308-312.

84 paz,18-65 anni,ASA 1 & 2
procedure elettive minori extraddominali ed
extratoraciche
anestesia a 1.5 MAC(DES 4.2%,SEVO 1.05%,ISO
0.75%)+N2O 70%. Vs TIVA Propofol/fentanil.
Monitoraggio neuromuscolare: Tof Guard con Tof
ogni 12 sec
dosi cumulative di cisatracurium 15 µg/kg fino a T1
5%.quando equilibrio fra Fi/Fe del vapore

Risultati dello studio di Wulf
et al.
100%
90%
80%
70%
60%
depressione %
50%
di T1
40%
30%
20%
10%
0%

*

*
DES
ISO
SEVO
TIVA

*
15 mu/kg

30 mu/kg
dosi di cisatracurium


45 mu/kg

Durate cliniche del
cisatracurium
45

*

40

*

35
30
min

25

*

20
15

DES
ISO
SEVO
TIVA

*

10
5
0

T125%

RI25-75%


TOF0.70

Diagramma Log-probit delle curve dose-risposta del
cisatracurium e depressione del T1/T0 % :confronto fra 1.5
Mac di DES,ISO,SEVO e tiva (Wulf ).
d
e
p
r
e
s
s
i
o
n
e

100
T
1
/
T
0
%

DES
IS
SEVO
TIVA

10
15

30
microgr/kg di cisatracurium


45

: Turan G, Dincer E, Ozgultekm A, Akgun N.R Recovery from
neuromuscular block following infusion of cisatracurium using
either sevoflurane or propofol for anaesthesia.
Eur J Anaesthesiol. 2004 Sep;21(9):751-753
70

Sevoflurane 12%

60

propofol 75-150
microgr/kg/min

50
min

40
30
20
10
0

T1 25 dose bolo

T1 25 infus


RI 25-75

Tof 70

Riprese nm dopo cisatracurium in infusione :confronto fra
TIVA e isoflurane :da

Jellish WS, Brody M, Sawicki K, Slogoff S.
Recovery from neuromuscular blockade after either bolus and prolonged infusions of cisatracurium or
rocuronium using either isoflurane or propofol-based anesthetics. Anesth Analg. 2000 Nov;91(5):1250-5.

50
45
40
35
30
min 25
20
15
10
5
0

ISOflurane
propofol

T1 25

T1 75

TOF 0.70


RI 25-75

Potenziamento del cisatracurium con gli
anestetici alogenati vs propofol
Turan :sevo 1-2% :Tof 70 +8%
Ortiz:desf >sevo>isof :RI e Tof 70 +
Melloni: sevo 1.5 e 2 Mac: + ED95
Hemmerling:IR di cis meno con
desf,sevo,isof
Jellish isof=sevo :TOF 70 +


Hemmerling TM, Schuettler J, Schwilden H. Desflurane
reduces the effective therapeutic infusion rate (ETI) of
cisatracurium more than isoflurane, sevoflurane, or
propofol.Can J Anaesth. 2001 Jun;48(6):532-7.


Cisatracurium nell’obeso


Tempi di ripresa dopo cisatracurium 0.2 mg/kg

Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A.The effects of cisatracurium on
morbidly obese women.
Anesth Analg. 2004 Oct;99(4):1090-4

200

Cisatr 0.2 mg/kg
Remifentanil propofol

180
160
140
120

*

100

obesi RBW
obesi IBW
normali RBW

80
60
40
20
0
onset sec

dur 25%min


dose mg

Messaggio da portare a casa per il cisatracurium
Dose iniziale e supplementari basate
sull’IBW


Mean infusion rates
Cisatracurium/atracurium:

» The infusion rates for a 95% ± 4% neuromuscular
block were 1.5 ± 0.4 µg × kg-1 × min-1 for
cisatracurium and 6.6 ± 1.7 µ g × kg-1 × min-1
for atracurium, 3.3 times those of cisatracurium
when referenced to the active cations. After the
infusion, the spontaneous recovery intervals 25%–
75% of 18 ± 11 min and 18 ± 8 min for
cisatracurium and atracurium (P = 0.896) were
shortened to 5 ± 2 min and 4 ± 3 min (P = 0.921)
after neostigmine.Mellinghoff,et al

Cisatracurium
µg/kg/min
3.1 ± 1:Jellish
1.5 ± 0.4:Mellinghoff
0.75/1 Cammu
61.7 ± 25.3 µg/m2/min Hemmerling
0.81 ± 0.02 -MIller


In conclusione: il cisatracurium è il
miorilassante ideale?
Onset e durata brevi :per l’intubazione:NO
Effetti riproducibili in tutte le categorie di pazienti:per il
mantenimento:SI
Recupero rapido e prevedibile in tutte le categorie di
pazienti e con ogni tipo di anestesia:SI
»
»
»
»

Eliminazione non organo dipendente
No istamino liberazione
Farmacocinetica e dinamica prevedibili
Stabilità cardiovascolare

Bassa incidenza di effetti avversi:SI

Ce la racconti bella ma…

…quanto costa???


Costi
Cost of care ≠ acquisition cost
The real, substantial savings accrue from use of intermediate- and
short-acting drugs because:
• Inexpensive, long-acting drugs are associated with prolonged
postoperative recovery (Ballantyne JC, et al. Anesth Analg. 1997; 85:476
Fast recovery means shorter risk periods of residual blockade. This
translates into fewer postoperative complications(2Berg H, et al. Acta
Anaesthesiol

1

Scand.

• Postoperative
complications
are
very
Avoiding these is where the real cost savings accrue

1997;41:1095

expensive

The economic of newer anaesthetic drugs: should we take
the Rolls-Royce or the bicycle today?
Fazi L, Watcha MF. Paed.Anaesth., 1999, 9(3):181-185


evitare l’impiego di NBM a lunga
durata
a favore dei composti a durata
breve-intermedia
Viby Mogensenn, 1997









Nmb-J Viby Mogensen-Min.An.2000

conclusioni


Nmb: la scelta di Viby Mogensen
intubazione di emergenza

succinicolina o rocuronio

durata imprevedibile

mivacurio

durata < 30 minuti

mivacurio

durata 30-60 minuti

NMB a durata intermedia

durata > 60 minuti

cisatracurio
NMB a durata intermedia

paz. cardiopatici

cisatracurio o vecuronio

paz con insufficienza
d'organo

cisatracurio o atracurio

paz allergici o asmatici

Cisatracurio o vecuronio

terapia intensiva

cisatracurio
Viby Mogensen, 2000


NMB:Indicazioni
pediatria

ICU

inf.conti

T.cesareo

da ricost
diluire

freddo

NO

NO

SI

(NO)

NO

SI

mivacurio

SI
> 2 anni

NO

SI

NO

NO

NO

atracurio

SI
da 1 mese

SI

SI

SI

NO

SI

cisatracurio

SI
da 1 mese

SI

SI

NO

NO

SI

rocuronio

SI
da 1 mese

NO

SI

NO

NO

SI

vecuronio

SI
da 5 mesi

NO

SI

SI

NO

SI non spec
da che età

SI

NO

NO

SI

succinilcolina

pancuronio


SI

NO

In quale modo cisatracurium ha
migliorato l’uso del curaro?
 Prevedibilità
 Anche in pazienti particolari
 Stabilità emodinamica
 Scarso rischio anafilassi
 Indicazione ICU in RCP

NIMBEX
FORMULAZIONI
NIMBEX 2
(2 mg/ml)

NIMBEX 5

5 fiale da ml 2,5
5 fiale da ml 5
5 fiale da ml 10

(mg.5)
(mg.10)
(mg.20)

1 flaconcino da ml 30

(mg.150)

(5 mg/ml)


FINE


prolonged infusions of cisatracurium or rocuronium using
either isoflurane or propofol-based anesthetics. Anesth Analg.
2000 Nov;91(5):1250-5.

Fin qui

» Department of Anesthesiology, Loyola University Medical
Center, Maywood, Illinois 60153, USA. wjellis@luc.edu
» We examined the recovery characteristics of cisatracurium or
rocuronium after bolus or prolonged infusion under either
isoflurane or propofol anesthesia. Sixty patients undergoing
neurosurgical procedures of at least 5 h were randomized to
receive either isoflurane with fentanyl (Groups 1 and 2) or
propofol and fentanyl (Groups 3 and 4) as their anesthetic.
Groups 1 and 3 received cisatracurium 0.2 mg/kg IV bolus,
spontaneously recovered, after which time an infusion was
begun. Groups 2 and 4 received rocuronium 0.6 mg/kg IV,
spontaneously recovered, and an infusion was begun. Before
the end of surgery, the infusion was stopped and recovery of
first twitch (T(1)), recovery index, clinical duration, and trainof-four (TOF) recovery was recorded and compared among
groups by using appropriate statistical methods. Clinical
duration was shorter for rocuronium compared with
cisatracurium using either anesthetic. Cisatracurium T(1)
75% recovery after the infusion was shorter with propofol

Table 3

Table 3. Mean Infusion Rates Compared Among Groups Over TimeAll rates are
µg · kg-1 · min-1 and represented as mean ± sd.The first six 10-min periods were
used for infusion adjustments and were not included in the data analysis. Average
infusion rate was calculated by adding the hourly rate after 180 min and dividing
by the remaining number of hours the infusion was maintained. ISO/CIS =
patients receiving isoflurane and cisatracurium, PROP/CIS = patients receiving
total IV anesthesia with propofol and cisatracurium, ISO/ROC = patients
receiving isoflurane e Rianimazione Ospedale di Faenza(RA)
and rocuronium, PROP/ROC = patients receiving total IV
Servizio di Anestesia

Table 2


of muscle relaxant. Iso/Cis = patients receiving isoflurane and cisatracurium, Prop/Ci
um. *P < 0.05 compared with Iso/Cis.


Tran TV, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of
cisatracurium after a short infusion in patients under propofol anesthesia.
Anesth Analg 1998; 87:1158-63.
mean terminal half-life of cisatracurium was 23.9 ± 3.3 min
total clearance averaged 3.7 ± 0.8 mL × min-1 × kg-1.
Using this model, the volume of distribution at steady state was significantly increased
compared with that obtained when central elimination only was assumed (0.118 ± 0.027
vs 0.089 ± 0.017 L/kg).
The effect-plasma equilibration rate constant was 0.054 ± 0.013 min-1.
The 50% effective concentration (153 ± 33 ng/mL) was 56% higher than that reported in
patients anesthetized with volatile anesthetics, which suggests that, compared with
inhaled anesthetics, a cisatracurium neuromuscular block is less enhanced by propofol.
Implications:
The drug concentration-effect relationship of the muscle relaxant cisatracurium has been
characterized under balanced and isoflurane anesthesia. Because propofol is now widely
used as an IV anesthetic, it is important to characterize the biological fate and the
concentration-effect relationship of cisatracurium under propofol anesthesia as well.


Curve individuali delle concentrazioni plasmatiche dopo 0.1
mg/kg di cisatracurium in tiva e andamento del blocco nm.
Tran TV, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of cisatracurium after a short infusion in
patients under propofol anesthesia. Anesth Analg 1998; 87:1158-63.

Blocco nm

Curve di decadimento


Blocco nm/curve di concentrazione nel
compart. effetto Tran TV, Fiset P, Varin F. Pharmacokinetics and pharmacodynamics of

cisatracurium after a short infusion in patients under propofol anesthesia. Anesth Analg 1998; 87:1158-63.


EC50 cisatracurium
TRAN 153 ± 33 ng/mL
SOROSHIAN 98+30


Atracurium:µg/kg/min
4.0 ± 0.7 / 5.0 ± 1.0
6.6 ± 1.7
» Mellinghoff

0.25–0.44 mg/ kg/ h=4.16 / 7.3
Ross, J. J.; Mason, D. G.; Linkens, D.
A.; Edwards, N. D.Self-learning fuzzy
logic control of neuromuscular block
Br. J. Anaesth. 1997; 78:412-415

But several studies reported that the effect site
concentration depressing twitch tension 50% (C50) varies
as a function of dose.
Bergeron L, Bevan DR, Berrill A, Kahwaji R, Varin F: Concentration–effect relationship of
cisatracurium at three different dose levels in the anesthetized patient. Anesthesiology 95:314–
23, 2001
Bragg P, Fisher DM, Shi J, Donati F, Meistelman C, Lau M, Sheiner LB: Comparison of twitch
depression of the adductor pollicis and the respiratory muscles. Anesthesiology 80:310–9, 1994
Fisher DM, Szenohradszky J, Wright PMC, Lau M, Brown R, Sharma M: Pharmacodynamic
modeling of vecuronium-induced twitch depression. Anesthesiology 86:558–66, 1997
Sorooshian SS, Stafford MA, Eastwood NB, Boyd AH, Hull CJ, Wright PMC: Pharmacokinetics
and pharmacodynamics of cisatracurium in young and elderly adult patients. Anesthesiology
84:1083–91, 1996


Cisatracurium
Based on the pharmacokinetic–
pharmacodynamic data of Bergeron et
al. for the 75-µg/kg dose, we estimated
that the doses producing 20% (ED20),
50% (ED50), 80% (ED80), and 99%
(ED99) effect were approximately 30,
37.5, 45, and 75 µg/kg, respectively.


Time of C peak and Keo variano
al variare della dose!!


La determinazione dei parametri farmacocinetici dipende
dalla descrizione più accurata possibile dell’andamento
iniziale della Cp
“estimation of pharmacodynamic parameters
depends on an accurate description of the
early time course of Cp.”
– Ducharme J, Varin F, Bevan DR, Donati F: Importance of
early blood sampling on vecuronium pharmacokinetic and
pharmacodynamic parameters. Clin Pharmacokinet
24:507–18, 1993

» For example, to demonstrate that vecuronium’s
C50 varied with dose (as was suggested by Bragg
et al., who modeled pharmacodynamics without
plasma concentration data), Fisher et al. sampled
arterial plasma at 0.5 min (in addition to a sampling
regimen similar to that of Bergeron et al.

L’andamento iniziale della Cp dipende dal sito di
campionamento….
Our simulations indicate the importance of early samples when effect peaks early. If
early samples cannot be obtained, pharmacodynamic modeling may be flawed.
Another design issue that could lead to incorrect modeling of the early plasma
concentration-versus-time course is the use of venous samples. For example, Donati
et al. demonstrated that atracurium’s arterial Cp is markedly larger than venous Cp

arterial Cp accurately
describes the input to the neuromuscular
junction, use of venous samples may lead to inaccurate estimates of
during the initial 2 min. In that

pharmacodynamic parameters. The inaccuracy of pharmacodynamic parameters is
likely to be largest for those drugs with the largest difference between arterial and
venous Cp values. If arterial blood cannot be sampled (e.g., for ethical reasons), then
the dosing regimen should be designed so as to minimize the difference between
arterial and venous Cp during times critical for the pharmacodynamic analysis. This
can presumably be accomplished by administering the muscle relaxant as a brief
infusion, as was suggested originally by Sheiner et al.

Piccoli errori nel timing di
somministrazione producono …….


Quindi

Problemi pratici di
applicazione degli
studi PK/Pd

Anesth Analg. 2006 Mar;102(3):738-43. Links
»

Pharmacokinetics and pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in
children during N2O/O2/propofol anesthesia.
–
–
–

»
»

Imbeault K,
Withington DE,
Varin F.

Faculte de Pharmacie, Universite de Montreal, Department of Anesthesia, Montreal Children's
Hospital/McGill University, Montreal, Quebec, Canada.
We studied the pharmacokinetics and pharmacodynamics of cisatracurium in 9 children (mean weight,
17.1 kg) aged 1-6 yr (mean, 3.75 yr) during propofol-nitrous oxide anesthesia. Neuromuscular
monitoring was performed. Venous samples were taken before injection of a 0.1 mg/kg dose of
cisatracurium and then at 2, 5, 10, 30, 60, 90, and 120 min. Cisatracurium plasma concentrations
were determined by high performance liquid chromatography. Onset time was 2.5 +/- 0.8 min,
recovery to 25% of baseline twitch height was 37.6 +/- 10.2 min, and the 25%-75% recovery index
was 10.9 +/- 3.7 min. Distribution and elimination half-lives were 3.5 +/- 0.9 min and 22.9 +/- 4.5 min,
respectively. Steady-state volume of distribution (0.207 +/- 0.031 L/kg) and total body clearance (6.8
+/- 0.7 mL/min/kg) were significantly larger than those published for adults. Pharmacodynamic results
were comparable to those obtained in pediatric studies during halothane or opioid anesthesia with the
exception of a longer recovery to 25% baseline. Although the plasma-effect compartment equilibration
rate constant was twofold faster (0.115 +/- 0.025 min(-1)) than that published for cisatracurium in
adults, the effect compartment concentration corresponding to 50% block was similar (129 +/- 27
ng/mL


Arain SR,Kern S, Ficke DJ, Ebert TJ.
Variability of duration of action of neuromuscular-blocking drugs in
elderly patients. Acta Anaesthesiol Scand. 2005 Mar;49(3):312-5.
: Steroid-based, non-depolarizing neuromuscular-blocking (NMB) drugs
(e.g. rocuronium, vecuronium) are characterized by organ-dependent
elimination and significantly longer durations of action in elderly
compared to young patients. Cisatracurium is a benzylisoquinolinium
NMB drug with a duration of action not altered by ageing. The objective
of the study was to determine if elderly patients had less variability in
duration of action with 2 x ED95 of cisatracurium compared to
equipotent doses of rocuronium or vecuronium. METHODS: Informed
consent was obtained from 66 elderly patients with normal renal and
liver function. Preoperative midazolam (1 mg) was given IV. The
anaesthestic induction was with 5 mg kg(-1) thiopental and 2 microg
kg(-1) fentanyl. The patients received 0.6 mg kg(-1) rocuronium, 0.1 mg
kg(-1) vecuronium or 0.1 mg kg(-1) cisatracurium. Anaesthetic
maintenance was with sevoflurane in oxygen/nitrous oxide.
Neuromuscular-blocking duration of action was defined as the return of
T1 twitch height to 25% of control. Variability was determined by
subtracting the actual duration of action from the mean duration of
Servizio
Anestesia e Rianimazione Ospedale di Faenza(RA)
action fordieach drug. RESULTS: The durations of action (range, min)

Kopman AF,Zank LM,Ng J,Neuman GG. Antagonism of Cisatracurium
and Rocuronium Block at a Tactile Train-of-Four Count of 2: Should
Quantitative Assessment of Neuromuscular Function Be Mandatory?
Anesth Analg 2004; 98:102-6.
ABSTRACT: With a train-of-four (TOF) ratio > 0.70 as the standard of acceptable
recovery, postoperative residual paralysis is a frequent occurrence in postanesthesia care
units (PACUs). However, detailed information regarding prior anesthetic management is
rarely provided. We examined the incidence of postoperative weakness after the
administration of cisatracurium and rocuronium when using a rigid protocol for muscle
relaxant and subsequent neostigmine administration. Under desflurane, N2O, and opioid
anesthesia, tracheal intubation was accomplished after either cisatracurium 0.15 mg/kg or
rocuronium 0.60 mg/kg. The response of the thumb to ulnar nerve stimulation was
estimated by palpation. Additional increments of muscle relaxant were given as needed to
maintain the TOF count at 1 or 2. At the conclusion of surgery, at a TOF count of 2,
neostigmine 0.05 mg/kg plus glycopyrrolate 10 µg/kg was
administered. The mechanical TOF response was then measured with a force transducer
starting 5 min postreversal. Patients were observed until a TOF ratio of 0.90 was achieved.
There were no significant differences in the recovery profiles of cisatracurium versus
rocuronium. TOF ratios at 10 min postreversal were 0.72 ± 0.10 and 0.76 ± 0.11,
respectively. At 15 min postreversal, only one subject in each group had a TOF ratio of <
0.70. No patient in either group arrived in the PACU with a TOF ratio < 0.70. Our results
suggest that if cisatracurium or rocuronium is administered by using the TOF count as a
guide, critical episodes of postoperative weakness in the PACU should be an infrequent
Servizio
occurrence. di Anestesia e Rianimazione Ospedale di Faenza(RA)

Kopman AF,Zank LM,Ng J,Neuman GG. Antagonism of Cisatracurium
and Rocuronium Block at a Tactile Train-of-Four Count of 2: Should
Quantitative Assessment of Neuromuscular Function Be Mandatory?
Anesth Analg 2004; 98:102-6


J., F.R.C.A.§; Wright, Peter M.C.,
M.D., F.F.A.R.C.S.I., †
Background: The effects of a muscle relaxant may differ in elderly compared with young adult patients
for a variety of reasons. The authors compared the effects of a new muscle relaxant (cisatracurium) in
young and elderly adults and used pharmacokinetic/pharmacodynamic modeling to identify factors
explaining differences in time course of effect.
Methods: Thirty-one young (18—50 yr) and 33 elderly (>65 yr) patients anesthetized with nitrous oxide,
isoflurane, and fentanyl were studied. Cisatracurium (0.1 mg/kg) was given after induction of anesthesia
and later additional boluses of 0.025 mg/kg or an infusion of cisatracurium was given. Neuromuscular
transmission was measured using the first twitch of the train-of-four response at the adductor pollicis after
supramaximal stimulation of the ulnar nerve at 2 Hz every 15 s. Five venous blood samples were
obtained for plasma drug concentration at intervals ranging from 2 to 120 min from every patient. Three
additional samples were obtained from those who received an infusion. A population
pharmacokinetic/pharmacodynamic model was fitted to the plasma concentration and effect data. The
parameters of the model were permitted to vary with age to identify where differences existed between
young and elderly adults.
Results: Onset of block was delayed in the elderly; values being mean 3.0 (95% confidence interval
1.75—11.4) min and 4.0 (2.4—6.5) min in the young and elderly, respectively (P < 0.01). Duration of
action was similar in the two groups. Plasma clearance was 319 (293—345) ml/min in the study
population and did not differ between young and elderly patients. Apparent volume of distribution was
13.28 (9.9—16.7) l and 9.6 (7.6—11.7) l in the elderly and young adults, respectively (P < 0.05). There
also were differences in pharmacodynamic parameters between the young and elderly; the predominant
change being a slower rate of biophase equilibration (ke0) in the elderly (0.060 [0.052—0.068])/min
compared with the young (0.071 [0.065—0.077]/min; P < 0.05).
Conclusions: The pharmacokinetics of cisatracurium differ only marginally between young and elderly
adults. Servizio di Anestesia ein the elderly because of slower biophase equilibration.
Onset is delayed Rianimazione Ospedale di Faenza(RA)

Imbeault K, Withington DE, Varin F. Pharmacokinetics and
pharmacodynamics of a 0.1 mg/kg dose of cisatracurium besylate in
children duringN2O/O2/propofol anesthesia.Anesth Analg. 2006
Mar;102(3):738-43
Cisatracurium has a unique organ-independent elimination called Hofmann elimination
that depends solely on pH and temperature and accounts for 77% of the Cltot (21). As
expected with this type of elimination, the PKs of cisatracurium are linear up to 0.3
mg/kg (22). Only in adults have PK studies of cisatracurium been performed during
propofol anesthesia (10). Our PK data indicate that both half-lives for the distribution
and elimination rate constants are similar to those reported in adults. This is consistent
with previous observations made for atracurium in which the elimination half-life was
shown to be similar in infants, children, and adults (23).
To calculate the apparent volume of distribution (an exit-site dependent parameter),
the elimination rate from the peripheral compartment was assumed to be equal to the
mean in vitro degradation rate in plasma published by Welch et al. (17). In a previous
study (9), this value proved to be equal to or higher than the corresponding elimination
rate from the central compartment in 4 of 48 patients, resulting in a null or negative
organ clearance (model mis-specification). This limitation was not observed in our
study. In our opinion, the difference in pH between plasma and tissue interstitial fluid is
not large enough to significantly alter cisatracurium elimination.
In our patients, an almost twofold increase in the volume of distribution and Cltot of
cisatracurium was observed when compared with adults (10). Parallel changes
(approximately 20%) in the apparent Vss and Cltot of atracurium have also been
reported with increasing age (23); the progressive decrease in the extracellular fluid
Servizio
results in a di Anestesia e Rianimazione Ospedale di Faenza(RA)
proportional diminution of organ-independent elimination. These findings

Pharmacological studies have been performed in children with cisatracurium
during inhaled (3,5–7,18) and opioid (3–5) anesthesia but not during propofol
anesthesia. Using a similar dose, the effect data for our patients showed a
comparable onset time (2.5 min) to that obtained during nitrous oxide/opioid
anesthesia (2.3 min) (3) and halothane anesthesia (2.2 min or 2.5 min) (3,6), but
the clinical duration (recovery time to 25% of baseline twitch height) was 38 ± 10
min in our patients, longer than that observed for the opioid group in Meretoja et
al.’s (3) study (27 min; range, 24–33 min). In fact, it was comparable to that
observed in Taivainen et al.’s study (19) (36 ± 5 min), in which a larger dose
(0.15 mg/kg) was administered during N2O/opioid anesthesia. Thus, in the light
of our effect data alone, one would suggest that propofol has an enhancing
effect on neuromuscular blockade, comparable to that seen in adults receiving
inhaled anesthetics. However, in Meretoja et al. s’ study, the clinical duration of
cisatracurium in children during inhaled anesthesia (34 min; range, 22–40 min)
was within the range observed for the opioid group (3). Because no comparative
study was conducted, it is difficult to exclude the possibility that the longer
clinical duration observed in our children is not merely the result of a different
anesthetic setting.
In our patients, the recovery index from 25% to 75% of baseline twitch height
(11 ± 4 min) was virtually identical to that reported in the abovementioned
studies (3,6,19). This observation suggests that although the biological half-life

Tof count unreliable in the
reversal of deep rocu or cisatrac
block
J Clin Anesth. 2005 Feb;17(1):30-5. Links
» Antagonism of profound cisatracurium and rocuronium
block: the role of objective assessment of
neuromuscular function.
– Kopman AF,
– Kopman DJ,
– Ng J,
– Zank LM.
» Department of Anesthesiology, New York Medical College,
Valhalla, NY, USA. akopman@svcmcny.org
» STUDY OBJECTIVE: The purpose of this study is to
determine the incidence of significant (train-of-four [TOF]
ratio <0.70), but clinically undetectable (TOF ratio >0.40),
residual neuromuscular block after neostigmine antagonism
of profound cisatracurium (CIS) or rocuronium (ROC) block.
Servizio di Anestesia eProspective, randomized, open-label study.
DESIGN: Rianimazione Ospedale di Faenza(RA)

» .The effect of chronic anticonvulsant therapy
(CAT) on the maintenance and recovery
profiles of cisatracurium-induced
neuromuscular blockade has not been
adequately studied. In this study, we compared
the pharmacokinetics and pharmacodynamics
of cisatracurium after a prolonged infusion in
patients with or without CAT. Thirty patients
undergoing intracranial surgery were enrolled
in the study: 15 patients under CAT
(carbamazepine and phenytoin, Group A) and
15 controls receiving no anticonvulsant therapy
(Group C). Anesthesia was standardized and
both groups received a bolus of cisatracurium
followed by an infusion to maintain a 95%


Generalità sui miorilassanti


Elementi di sicurezza dei
Elementi di sicurezza dei
miorilassanti
miorilassanti

good
good
shelf life
shelf life

fast
fast
onset
onset

fast offset
fast offset

organ
organ
independent
independent

no residual
no residual
curarization
curarization

safety
safety

no histamine release
no histamine release

lack of
lack of
cardiovascular
cardiovascular
effects
effects


non cumulative
non cumulative

no active
no active
metabolites
metabolites

metabolismo
“plasmatico”:atracurium,cisatracurium
pseudocolinesterasico:mivacurium,SCC
esterasico:atracurium,(cisatracurium)
epatico:vecuronium,rocuronium,panc


Breve
Scc,Miva

Intermedia
Atrac,Cisatrac,Vecu,Rocu

Lunga
Panc,Doxa,Pipec.


liberaz
istamina

Benzilisochinoline
Benzilisochinoline

Effetti
emodinamici
emodinam ici


intsabilità
chimica

meno
liberaz
istamina

Aminosteroidei

maggiore
stabilità
cardiovasc.

Stabilità
chimica

struttura chimica
benzilisochinoline:
atrac,cisatrac,miva
liberazione istaminica
maggiore instabilità chimica

aminosteroidei:
panc,vecu,rocu,org 9487
stabilità frequenza cardiaca
maggiore stabilità chimica


criteri di scelta:
:

rapidità iot succi,rocuronium
brevità di azione:succinilcolina,mivacurium
non
cumulatività:atracurium,cisatracurium,mivacurium
insufficienza epatica e/o
renale:atracurium,cisatracurium
stabilità cardiovascolare:vecuronium,cisatracurium
costi:pancuronium

scelta dipendente anche da:
durata intervento
stato clinico del paziente:asmatici,......
interazioni farmacologiche
disponibilità strumentazione:pompe per
infusione,monitoraggio.....
costi


Costi
Diretti:
acquisto
conservazione
indiretti:
trattamento ;
lib istamina
mialgie
bocca secca
PONV…..

prolungamento degenza,:sala op,RR,Pacu...
Ospedalizzazione non prevista
aumento del discomfort,ansietà,stress…

Dosi di
laudanosina(µg/ml):subepilettogene….
1,2
1
0,8
Fahey 1984
Chapple 1987
Lien 1996

0,6
0,4
0,2
0

atrac 2 ED95

atrac


cis 4 ED95

Concentrazioni di laudanosina
dalla letteratura
6

0,7-1.9 mg/kg/hr per 40-139 hr,ICU

↓

5
4
microgr/ml 3

Fahey 1984
Ward 1985
Ward 1986
Yate(1985)

↓

2
1
0

normali


insuff renale

Problemi della laudanosina
Metabolismo:
» 70% biliare
» 30% renale

metabolizzazione
epatica?:tetraidropa
paverina?
Rapporto
CSF/plasma:0.30.6(Fahey 1985)

Hennis( 1985):segni
di risveglio dopo
bolo di 2 mg/kg(cani
in anestesia
alotanica):
Miller (1985): Mac
dell’alotano
aumentato del 30%
nei conigli a conc
tra 0.4-0.8 µg/ml


Tran, Tuong-Vi, BPharm*; Fiset, Pierre, MD†; Varin, France, PhD*
*Faculté de Pharmacie, Université de Montréal; and †Department of Anaesthesia, Royal Victoria Hospital, McGill
University, Montreal, Canada
This study was funded in part by Glaxo Wellcome Canada.
Presented in part at the annual meeting of the American Society of Anesthesiologists, New Orleans, LA, October 19–23,
1996.
Accepted for publication July 8, 1998.
Address correspondence and reprint requests to France Varin, PhD, Faculté de Pharmacie, Université de Montréal, C.P.
6128, succursale Centre-ville, Montréal, Québec, Canada H3C 3J7.
ABSTRACT: Fourteen patients, ASA physical status I or II, were recruited to assess the pharmacokineticpharmacodynamic relationship of cisatracurium under nitrous oxide/sufentanil/propofol anesthesia. The electromyographic
response of the abductor digiti minimi muscle was recorded on train-of-four stimulation of the ulnar nerve. A 0.1-mg/kg
dose of cisatracurium was given as an infusion over 5 min. Arterial plasma concentrations of cisatracurium and its major
metabolites were measured by using high-performance liquid chromatography. A nontraditional two-compartment
pharmacokinetic model with elimination from central and peripheral compartments was used. The elimination rate constant
from the peripheral compartment was fixed to the in vitro rate of degradation of cisatracurium in human plasma (0.0237
min-1). The mean terminal half-life of cisatracurium was 23.9 ± 3.3 min, and its total clearance averaged 3.7 ± 0.8 mL ×
min-1 × kg-1. Using this model, the volume of distribution at steady state was significantly increased compared with that
obtained when central elimination only was assumed (0.118 ± 0.027 vs 0.089 ± 0.017 L/kg). The effect-plasma equilibration
rate constant was 0.054 ± 0.013 min-1. The 50% effective concentration (153 ± 33 ng/mL) was 56% higher than that
reported in patients anesthetized with volatile anesthetics, which suggests that, compared with inhaled anesthetics, a
cisatracurium neuromuscular block is less enhanced by propofol. Implications: The drug concentration-effect relationship of
the muscle relaxant cisatracurium has been characterized under balanced and isoflurane anesthesia. Because propofol is
now widely used as an IV anesthetic, it is important to characterize the biological fate and the concentration-effect
relationship of cisatracurium under propofol anesthesia as well.

De Wolf AM.,Freeman JA, Scott VL,Tullock W,Smith
DA,Kisor DF, Kerls S,Cook,DR. Pharmacokinetics and
pharmacodynamics of cisatracurium in patients with endstage liver disease undergoing liver transplantation.
Br. J. Anaesth. 1996; 76:624-628
: We determined the pharmacokinetics and pharmacodynamics of cisatracurium, one of the
10 isomers of atracurium, in 14 patients with end-stage liver disease undergoing liver
transplantation and in 11 control patients with normal hepatic and renal function undergoing
elective surgery. Blood samples were collected for 8 h after i.v. bolus administration of
cisatracurium 0.1 mg kg-1 (2´ED95). Plasma concentrations of cisatracurium and its
metabolites were determined using an HPLC method with fluorescence detection.
Pharmacokinetic variables were determined using non-compartmental methods.
Neuromuscular block was assessed by measuring the electromyographic evoked response
of the adductor pollicis muscle to train-of-four stimulation of the ulnar nerve using a PuritanBennett Datex (Helsinki, Finland) monitor. Pharmacodynamic modelling was completed
using semi-parametric effect-compartment analysis. Volume of distribution at steady state
was 195 (SD 38) ml kg-1 in liver transplant patients and 161 (23) ml kg-1 in control patients
(P < 0.05), plasma clearance was 6.6 (1.1) ml kg-1 min-1 in liver transplant patients and 5.7
(0.8) ml kg-1 min-1 in control patients (P < 0.05), but elimination half-lives were similar: 24.4
(2.9) min in liver transplant patients vs 23.5 (3.5) min in control patients (ns). The time to
maximum block was 2.4 (0.8) min in liver transplant patients compared with 3.3 (1.0) min in
control patients (P < 0.05), but the clinical effective duration of action (time to 25% recovery)
was similar: 53.5 (11.9) min in liver transplant patients compared with 46.9 (6.9) min in
control patients (ns). The recovery index (25-75% recovery) was also similar in both groups:
15.4 (4.2) min in liver transplant patients and 12.8 (1.9) min in control patients (ns). After
cisatracurium, peak laudanosine concentrations were 16 (5) and 21 (5) ng ml-1 in liver
transplant and control patients, respectively. In summary, minor differences in the
pharmacokinetics and pharmacodynamics of cis-atracurium in liver transplant and control
patients were not associated with any clinically significant differences in recovery profiles
after a single dose of cisatracurium.


Prielipp RC, Coursin DB, Scuderi PE, Bowton DL,
Ford SR, ardenas VJ Jr, Vender J, Howard D, Casale EJ, Murray MJ.
Comparison of the infusion requirements and recovery profiles of
vecuronium and cisatracurium 51W89 in intensive care unit patients.
Anesth Analg. 1995 Jul;81(1):3-12.

» prospective, randomized, double-blind, multicenter study in critically ill adults.
» 58 mechanically ventilated ICU patients from five medical centers were
randomized to receive either cisatracurium or VEC.
» Fifty-four of the 58 patients received NMB drugs before entering this study but
demonstrated at least partial recovery (> or = one twitch) in the train-of-four (TOF)
response before initiation of the NMB study drug.
» NMB drug infusion was titrated by peripheral nerve stimulation to maintain at least
one twitch in the TOF response.
» NMB drugs were infused for 1-5 days. After discontinuation of NMB drug infusion,
recovery of neuromuscular transmission was monitored with an accelerometer.
» NMB drug infusion for 28 cisatracurium patients averaged 2.6 +/- 0.2 (mean +/SEM) micrograms.kg-1.min-1 with a mean duration of 80 +/- 7 h.
» After discontinuing cisatracurium administration, recovery to 70% TOF ratio
averaged 68 +/- 13 min. The mean infusion rate for 30 VEC patients was 0.9 +/0.1 micrograms.kg-1.min-1 with a mean duration of 66 +/- 12 h.
» Neuromuscular recovery after VEC averaged 387 +/- 163 min, which was
significantly longer (P = 0.02) than that after cisatracurium. Prolonged recovery of
neuromuscular e Rianimazione Ospedale di Faenza(RA)
function after discontinuation of NMB drug infusion (identified by
Servizio di Anestesia
the primary investigator at each medical center) was reported in two cisatracurium

Reich DL, Hollinger I, Harrington DJ, Seiden HS,
Chakravorti S, Cook DR. Comparison of cisatracurium and
vecuronium by infusion in neonates and small infants after
congenital heart surgery. Anesthesiology. 2004 101(5):1122-7.
» BACKGROUND: Neonates and infants often require
extended periods of mechanical ventilation facilitated by
sedation and neuromuscular blockade. METHODS:
» Twenty-three patients aged younger than 2 yr were randomly
assigned to receive either cisatracurium or vecuronium
infusions postoperatively in a double-blinded fashion after
undergoing congenital heart surgery.
» The infusion was titrated to maintain one twitch of a train-offour. The times to full spontaneous recovery of train-of-four
without fade, extubation, intensive care unit discharge, and
hospital discharge were documented after drug
discontinuation. Sparse sampling after termination of the
infusion and a one-compartment model were used for
pharmacokinetic analysis. The Mann-Whitney U test and
Student t test were used to compare data between groups.
RESULTS: There were no significant differences between
groups with respect to demographic data or duration of
postoperative neuromuscular blockade infusion. The median

Burmester M, Mok Q.
Randomised controlled trial comparing cisatracurium and vecuronium
infusions in a paediatric intensive care unit.Intensive Care Med. 2005
May;31(5):686-92..
» OBJECTIVE: To evaluate and compare the efficacy, infusion rate and recovery
profile of vecuronium and cisatracurium continuous infusion in critically ill children
requiring mechanical ventilation. DESIGN AND SETTING: Prospective,
randomised, double-blind, single-centre study in critically ill children in a paediatric
intensive care unit in a tertiary children's hospital. METHODS: Thirty-seven
children from 3 months to 16 years old (median 4.1 year) were randomised to
receive either drug; those already receiving more than 6 h of neuromuscular
blocking drugs were excluded. The Train-of-Four (TOF) Watch maintained
neuromuscular blockade to at least one twitch in the TOF response. Recovery time
was measured from cessation of infusion until spontaneous TOF ratio recovery of
70%. RESULTS: The cisatracurium infusion rate in nineteen children averaged
3.9+/-1.3 microg kg(-1) min(-1) with a median duration of 63 h (IQR 23-88). The
vecuronium infusion rate in 18 children averaged mean 2.6+/-1.3 microg kg(-1)
min(-1) with a median duration of 40 h (IQR 27-72). Median time to recovery was
significantly shorter with cisatracurium (52 min, 35-73) than with vecuronium (123
min, 80-480). Prolonged recovery of neuromuscular function (>24 h) occurred in
one child (6%) on vecuronium. CONCLUSIONS: Recovery of neuromuscular
function after discontinuation of neuromuscular blocking drug infusion in children is
significantly faster with cisatracurium than vecuronium. Neuromuscular monitoring
was not sufficient to eliminate prolonged recovery in children on vecuronium
infusions.

Reich DL, Mulier J, Viby-Mogensen J, Konstadt SN,van Aken
HK,Jensen FS,De Perio M, Buckley S.
Comparison of the cardiovascular effects of cisatracurium and
vecuronium in patients with coronary artery disease
Can J Anaesth 1998 / 45 / 794-797
One hundred patients undergoing myocarcial revascularization participated in a pilot study
(seven patients) and a double-binded, randomized, controlled trial comparing the
haemodynamic effects of cisatracurium with vecuronium at three centres. The patients were
anaesthetized using oxygen 100%, with etomidate, fentanyl and a benzodiazepine, and
tracheal intubation was facilitated using succinylcholine. After baseline haemodynamic
measurements, the study drug was administered over 5–10 sec according to group
assignment: Group A (pilot) cisatracurium, 0.20 mg×kg-1 (4 x ED95), (n = 7); Group B
cisatracurium, 0.30 mg×k-1 (6 x ED95), (n = 31); Group C-vecuronium, 0.30 mg×kg-1 (6 x
ED95), (n = 31); Group D cisatracurium, 0.40 mg×kg-1(8 x ED95), (n = 21); Group Evecuronium. 0.30 mg×kg-1 (6 x ED95), (n = 10). The haemodynamic measurements were
repeated at 2, 5, and 10 min after cisatracurium or vecuronium.
Results: Two patients in Group D had >20% decreases in MAP but only one required therapy
for hypotension. The haemodynamic changes from pre- to post-injection in the cisatracurium
patients were minimal and similar to patients receiving vecuronium.
Conclusions: In patients with coronary artery disease, rapid cisatracurium (4–8xED95)
boluses and vecuronium 6xED95) result in minor, clinically insignificant haemodynamic side
effects.


RM. Evaluation of cisatracurium, a new neuromuscular
blocking agent, for tracheal intubation. CAN J ANAESTH
1996 / 43: 9 / pp925-31
Purpose: The primary objective of this study was a blinded, randomized comparison of the recommended intubating dose of atracurium (0.5 mg ×
kg-1) with an approximately equipotent dose of cisatracurium (0.1 mg × kg-1) during N2O/O2/propofol/fentanyl anaesthesia.
Methods: Eighty ASA physical status 1 or 2 patients, 18–70 yr of age, within 30% of ideal body weight, scheduled for elective low to moderate
risk surgical procedures were studied. Adductor pollicis evoked twitch responses were measured with a Grass FT 10 force displacement
transducer (Grass Instruments, Quincy, MA) and continuously recorded on a Gould multichannel polygraph (Gould Instrument Systems,
Cleveland, OH) after induction of anaesthesia.
Results: Increasing the initial dose of cisatracurium (from 0.1 to 0.15 and 0.2 mg × k-1, decreased mean time of onset (from 4.6 to 3.4 and 2.8
min, respectively), and increased mean time of clinically effective duration (45 to 55 and 61 min, respectively). Recovery to a T4:T1 ratio of 0.7
occurred approximately seven minutes following administration of the reversal agent neostigmine for all treatment groups. Intubation conditions
were good or excellent in over 90% of patients in all treatment groups (two minutes after approximately 2 x ED95 doses of cisatracurium or
atracurium and 1.5 minutes after 3 x and 4 x ED95 doses of cisatracurium).
Conclusion: The intubation results reported in this study together with the combination of predictable recovery from neuromuscular block and
apparent haemodynamic stability make cisatracurium a potentially useful muscle relaxant in clinical practice.
Objectif: Comparer aléatoirement et en aveugle la dose d'atracurium recommandée pour l'intubation (0,5 mg × kg-1) avec une dose
approximative équipotente de cisatracurium (0,1 mg × kg-1) pendant une anesthésie associant N2O/O2/propofol/fentanyl.
Méthodes: L'étude portait sur 84 patients ASA 1 et 2, âgés de 18 à 70 ans, dont le poids ne déviait pas de plus de 30% du poids idéal,
programmés pour une chirurgie non urgente comportant un risque faible ou modéré. Le twitch évoqué à l'adducteur du pouce était mesuré
après l'induction de l'anesthésie à l'aide d'un transducteur Grass FT 10 (Grass Instrument, Quincy, MA) et enregistré en continu sur un
polygraphe Gould (Gould Instrument System, Cleveland, OH).
Résultats: L'augmentation de la dose initiale de cisatracurium (de 0,1 à 0,15 et à 0,2 mg × kg-1) diminuait l'installation du bloc (respectivement
de 4,6 à 2,8 min) et augmentait la durée moyenne d'efficacité clinique (respectivement de 45 à 55 et à 61 min). La récupération à 0,7 du rapport
T4/T1 survenait environ sept minutes après l'administration de l'antagoniste néostigmine dans tous les groupes. Les conditions pour l'intubation
étaient de bonnes à excellentes chez plus de 90% des patients de tous les groupes (deux minutes après des doses d'environ 2 x ED50 de
cisatracurium ou d'atracurium et 1,5 min après 3 x et 4 x ED50 de cisatracurium).
Conclusion: Les résultats rapportés dans cette étude concernant l'intubation associés avec un récupération prévisible du bloc au cisatracurium
et sa stabilité hémodynamique apparente montrent que le cisatracurium pourrait être un relaxant musculaire utile en clinique.


Cisatracurium perchè

Recommandé

Recommandé

Contenu connexe

Similaire à Cisatracurium perchè

Similaire à Cisatracurium perchè (20)

Plus de Claudio Melloni

Plus de Claudio Melloni (20)

Dernier

Dernier (20)

Cisatracurium perchè

Notes de l'éditeur